South Africa Smoking Cessation and Engagement in HIV/TB Care Care
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMassachusetts General Hospital
About this trial
The purpose of this study is to integrate elements from existing interventions developed by our team into a single intervention (QUIT-AD), designed to improve smoking cessation and favorable HIV/TB treatment outcomes among individuals with HIV and/or TB in Cape Town, South Africa. If feasibility, acceptability, and preliminary efficacy are demonstrated, the intervention will be ready for large-scale effectiveness/implementation testing. This program will has the potential to dramatically improve public health by increasing the smoking quit rate and facilitating favorable HIV/TB treatment outcomes among patients with HIV and/or TB in resource limited South African settings.
Eligibility criteria
Qualifiers
Aged 18 or older
Willing and able to provide written informed consent
Living with HIV, confirmed via medical record, and on antiretroviral therapy (ART) AND/OR within 1 month of initiating or reinitiating TB treatment; positive GeneXpert test or sputum culture
Disqualifiers
Habitual use of other tobacco products
Current interfering untreated/unstable mental health condition (e.g., psychosis, bipolar dx)
Current use of non-study pharmacotherapy for smoking cessation,
Cognitive Behavioral Therapy for smoking cessation initiated within the past year,
Trial design
Treatments tested in this trial
- QUIT-AD
- Enhanced Treatment as Usual
Treatment groups
86 Participants
are divided into 2 treatment groupsSponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Boston University
Collaborator
University of Cape Town
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov